Background: Pegylated liposomal doxorubicin (PLD) and epirubicin are both superior variants of doxorubicin and are commonly applied as basic chemotherapeutics in breast cancer. However, the direct comparison of their efficacy and side effects has not been adequately reported. This study aimed to compare the efficacy and toxicity of PLD and epirubicin as neoadjuvant chemotherapy for invasive breast cancer.
Patients and methods: Women (n = 43) with invasive breast cancer who received neoadjuvant chemotherapy with the regimens containing PLD (PLD group) were analyzed and 1:2 matched with those (n = 86) who received regimens containing epirubicin (epirubicin group) according to clinical TNM staging and taxane combination.
Results: The PLD group achieved similar clinical response rate in neoadjuvant chemotherapy compared to the epirubicin group (76.7% vs 75.6%). The PLD group had a lower rate of grade 3 & 4 neutropenia (30.2% vs 60.5%), vomiting (7.0% vs 28.0%), and grade 3 & 4 alopecia (9.3% vs 43.0%), yet a higher rate of mouth ulceration (46.5% vs 11.7%). For the cardiac toxicity, the PLD group had a significantly lower rate of ventricular premature beat compared with the epirubicin group (7.0% vs 20.9%, p = 0.043), and cardiac ultrasonography monitoring showed non-significantly less PLD group patients' left ventricular ejection fraction decline more than 10% compared with the epirubicin group (4.7% vs 8.1%, p = 0.463).
Conclusion: In neoadjuvant chemotherapy for invasive breast cancer, PLD provides potentially similar efficacy and relatively less toxicity compared to epirubicin.
Keywords: breast cancer; efficacy; epirubicin; neoadjuvant chemotherapy; pegylated liposomal doxorubicin.